Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial - The Lancet Oncology
Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement | Leukemia
Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial -
Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan | International Journal of Hematology
Revlimid - NPS MedicineWise
Maintenance Therapy with Revlimid for Multiple Myelom
Treatment schema for newly diagnosed multiple myeloma and commonly used... | Download Scientific Diagram
Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma | Haematologica
Revlimid - NPS MedicineWise
Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma | Blood Cancer Journal
Carfilzomib/Lenalidomide/Dexamethasone → Lenalidomide Extended Dosing for Newly Diagnosed MM | Research To Practice
Multiple Myeloma Treatment Option | REVLIMID® (lenalidomide)
Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma - Lund - 2018 - Cancer Medicine - Wiley Online Library
Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone - ScienceDirect
Revlimid (Lenalidomide) Now FDA Approved as First-Line Therapy for Patients with Multiple Myeloma
When and How to Treat Relapsed Multiple Myeloma | American Society of Clinical Oncology Educational Book
Cancers | Free Full-Text | How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone in Myeloma
Velcade/Revlimid/Dexamethasone New Standard for Newly Diagnosed Multiple Myeloma - CancerConnect
547-Lenalidomide and dexamethasone oral | eviQ
Suggested approach to the treatment of patients with newly-diagnosed... | Download Scientific Diagram
Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial - The Lancet Haematology
Tip Card: The VRd Regimen by International Myeloma Foundation - Issuu
Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma | NEJM
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial | Blood Cancer Journal
Lenalidomide, Bortezomib, and Dexamethasone (RVD) Regimen for Multiple Myeloma. - Abstract - Europe PMC
Carfilzomib, Lenalidomide, and Dexamethasone vs Quadruplet Regimen Among Transplant-Eligible Patients With Newly Diagnosed MM on Vimeo
